Eye最新文献

筛选
英文 中文
Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma 新一代肿瘤学:CAR-T 细胞对眼部淋巴瘤和骨髓瘤的作用
IF 3.9 3区 医学
Eye Pub Date : 2024-09-12 DOI: 10.1038/s41433-024-03324-6
Mouayad Masalkhi, Noura Wahhoud, Ezzat Elhassadi
{"title":"Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma","authors":"Mouayad Masalkhi, Noura Wahhoud, Ezzat Elhassadi","doi":"10.1038/s41433-024-03324-6","DOIUrl":"https://doi.org/10.1038/s41433-024-03324-6","url":null,"abstract":"<p>Chimeric Antigen Receptor (CAR-T) cell therapy represents a groundbreaking advancement in the field of cancer immunotherapy, where it offers a highly targeted and personalized approach to cancer treatment [1]. Since its birth in 1993, this innovative therapy has been built upon the genetic engineering of a patient’s own T cells to express a chimeric antigen receptor (CAR), which is designed to recognize and bind to specific antigens present on cancer cells [1]. By reprogramming the immune system to better recognize and destroy malignant cells, CAR-T therapy improves the body's natural ability to fight cancer cells with unprecedented precision and effectiveness [1].</p><p>The therapeutic potential of CAR-T cells has been particularly promising in the treatment of hematological malignancies, such as lymphoma and multiple myeloma (MM) [2]. The ability to specifically target antigens, such as CD19 in B cell malignancies, CD20 in lymphomas, and CD138 in MM, allows for a more directed and efficient immune response and significantly reduces the off-target effects that often accompany traditional cancer treatments like chemotherapy or radiation [2, 3].</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kyrieleis plaques at optic nerve head in ocular toxoplasmosis 眼弓形虫病视神经头的凯里莱斯斑块
IF 3.9 3区 医学
Eye Pub Date : 2024-09-11 DOI: 10.1038/s41433-024-03328-2
Anamika Patel, Anup Kelgaonkar, Avinash Pathengay
{"title":"Kyrieleis plaques at optic nerve head in ocular toxoplasmosis","authors":"Anamika Patel, Anup Kelgaonkar, Avinash Pathengay","doi":"10.1038/s41433-024-03328-2","DOIUrl":"https://doi.org/10.1038/s41433-024-03328-2","url":null,"abstract":"<p>Kyrieleis plaques are focal segmental intra-arterial plaques that simulate arterial emboli and are seen in infectious uveitis conditions such as tuberculosis, toxoplasmosis, cytomegalovirus (CMV) retinitis, syphilis, and viral acute retinal necrosis [1, 2].</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials 不同抗血管内皮生长因子方案治疗新生血管性老年黄斑变性的两年疗效和安全性:随机对照试验网络荟萃分析
IF 3.9 3区 医学
Eye Pub Date : 2024-09-11 DOI: 10.1038/s41433-024-03327-3
Hong Sun, Ling Li, Fengjiao Bu, Xiu Xin, Jingchao Yan, Taomin Huang
{"title":"Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials","authors":"Hong Sun, Ling Li, Fengjiao Bu, Xiu Xin, Jingchao Yan, Taomin Huang","doi":"10.1038/s41433-024-03327-3","DOIUrl":"https://doi.org/10.1038/s41433-024-03327-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>To compare the 2-year efficacy and safety of various anti-vascular endothelial growth factor (VEGF) regimens for neovascular age-related macular degeneration (nAMD).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A comprehensive search was performed on multiple electronic databases up to April 2023 and updated in June 2024, to identify relevant randomized controlled trials (RCTs). Key outcomes included the proportion of patients achieving a vision gain of ≥15 letters and maintaining stable vision (loss of &lt;15 letters) in best-corrected visual acuity (BCVA), changes in mean BCVA from baseline, serious ocular adverse events (SAEs), adverse events leading to treatment discontinuation and any cause of death at 2 years.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Nineteen trials with 12,654 patients and 25 treatment regimens were analyzed in the study. All anti-VEGF regimens showed superior efficacy compared to sham therapy. Specifically, faricimab 6 mg (4+up to Q16W) and ranibizumab 0.5 mg (2-week T&amp;E) displayed top-level effect in vision gain. Bevacizumab 1.25 mg (2-week T&amp;E) and aflibercept 2 mg (2-week T&amp;E) demonstrated the most stable vision outcomes. Bevacizumab 1.25 mg (2-week T&amp;E) and ranibizumab 0.5 mg (2-week T&amp;E) exhibited the most pronounced mean BCVA improvement. Compared to sham therapy, the risk of SAEs was significantly higher for brolucizumab 6 mg (3 + Q12W/ Q8W) (RR = 6.04, 95% CI: 1.30–28.02) and PDS 100 mg/ml (Q24W) (RR = 10.95, 95% CI: 2.14–56.02), but not for other anti-VEGF regimens.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Ranibizumab 0.5 mg (2-week T&amp;E) emerges as a potentially optimal regimen for nAMD over a 2-year period. Future studies need to consider the impact of baseline characteristics on treatment outcomes.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors associated with acute retinal necrosis treated non-surgically 与急性视网膜坏死非手术治疗相关的预后因素
IF 3.9 3区 医学
Eye Pub Date : 2024-09-11 DOI: 10.1038/s41433-024-03319-3
Haihui Wei, WenJing Xu, Hai Jiang, Siyan Jin, Xiaoli Liu
{"title":"Prognostic factors associated with acute retinal necrosis treated non-surgically","authors":"Haihui Wei, WenJing Xu, Hai Jiang, Siyan Jin, Xiaoli Liu","doi":"10.1038/s41433-024-03319-3","DOIUrl":"https://doi.org/10.1038/s41433-024-03319-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>To analyse the prognostic factors for visual acuity in acute retinal necrosis (ARN) patients treated non-surgically.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The clinical data of ARN patients who visited our hospital from January 2010 to January 2023 were retrospectively analysed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Twenty-four patients (29 eyes) were included. Aqueous humour samples were collected from 20 out of 29 eyes, and PCR confirmed that 85% (17/20) of the eyes had VZV infection, 10% (2/20) had CMV infection, and 5% (1/20) had HSV infection. All patients were treated with intravenous antiviral agents. Intravitreal ganciclovir and oral corticosteroids were given according to the patients’ wishes. A comparison of visual acuity at the time of first identification of inactive ARN with that at the first visit revealed that 16 (55.2%) eyes improved and 13 (44.8%) did not improve. Logistic regression analysis revealed that risk factors for failure to improve vision after treatment included retinal detachment (odds ratio [OR],33.75; 95% CI, 3.245–351.067; <i>P</i> = 0.003), necrotising retinitis involving the posterior pole (odds ratio [OR],8.167; 95% CI, 1.297–51.403, <i>P</i> = 0.025), and arteritis involving the large retinal arteries (odds ratio [OR],9.167; 95% CI, 1.493–56.297; <i>P</i> = 0.017). The VZV viral load in the aqueous humour at initial presentation was significantly associated with visual prognosis (<i>r</i> = 0.688, <i>P</i> = 0.013), retinal detachment (<i>τ</i> = 0.597, <i>P</i> = 0.021) and the extent of retinal necrosis (<i>τ</i> = 0.57, <i>P</i> = 0.027). The neutrophil to lymphocyte ratio (NLR) of VZV-infected patients at first presentation was significantly correlated with the prognosis of visual acuity (<i>r</i> = 0.616, <i>P</i> = 0.033) and retinal detachment (<i>τ</i> = 0.728, <i>P</i> = 0.004).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>High NLR and viral DNA copy number in the aqueous humour at the initial presentation, as well as subsequent retinal detachment, necrotising retinitis involving the posterior pole, and arteritis involving the large retinal arteries were risk factors for poor visual prognosis in VZV-infected ARN patients.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying the root cause of lost lashes 找出睫毛脱落的根本原因
IF 3.9 3区 医学
Eye Pub Date : 2024-09-10 DOI: 10.1038/s41433-024-03332-6
Hui Mei Wong, Miles Kiernan
{"title":"Identifying the root cause of lost lashes","authors":"Hui Mei Wong, Miles Kiernan","doi":"10.1038/s41433-024-03332-6","DOIUrl":"https://doi.org/10.1038/s41433-024-03332-6","url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary vitreoretinal lymphoma and macular oedema 原发性玻璃体视网膜淋巴瘤和黄斑水肿
IF 3.9 3区 医学
Eye Pub Date : 2024-09-10 DOI: 10.1038/s41433-024-03330-8
Tingkun Shi Mmed, Haoyu Chen
{"title":"Primary vitreoretinal lymphoma and macular oedema","authors":"Tingkun Shi Mmed, Haoyu Chen","doi":"10.1038/s41433-024-03330-8","DOIUrl":"https://doi.org/10.1038/s41433-024-03330-8","url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meta-mistake: are fragile meta-analyses in ophthalmology worth the high cost? 荟萃误区:眼科中脆弱的荟萃分析是否值得高成本?
IF 3.9 3区 医学
Eye Pub Date : 2024-09-09 DOI: 10.1038/s41433-024-03331-7
Mattias Wei Ren Kon, William Rojas-Carabali, Carlos Cifuentes-Gonzalez, Rupesh Agrawal
{"title":"Meta-mistake: are fragile meta-analyses in ophthalmology worth the high cost?","authors":"Mattias Wei Ren Kon, William Rojas-Carabali, Carlos Cifuentes-Gonzalez, Rupesh Agrawal","doi":"10.1038/s41433-024-03331-7","DOIUrl":"https://doi.org/10.1038/s41433-024-03331-7","url":null,"abstract":"<p>We read with interest the article by Nanji et al., which details that meta-analyses in ophthalmology are frequently fragile, and their statistical significance hinges on the event status of very few patients [1]. We would like to add to this finding with information regarding the relevance of meta-analyses within ophthalmology and how we could improve their overall reliability (Table 1).</p><figure><figcaption><b data-test=\"table-caption\">Table 1 List of recommendations to enhance the reliability and utility of meta-analyses in ophthalmology.</b></figcaption><span>Full size table</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure><p>Meta-analyses were originally written to compile data across publications with similar research aims, to increase robustness and reliability of scientific research as a whole. However, with the current ease of reviewing literature, abundance of analytical software to simplify this process, new statistical techniques to generate different types of meta-analyses, and the relative accessibility given that meta-analyses do not require a lab setting, the number of meta-analyses published across all fields have starkly increased especially during the COVID-19 pandemic [2].</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Macular holes with minimal diameter greater than 650 µm close in 85% of cases after vitrectomy and ILM peeling with visual benefit 在玻璃体切除术和ILM剥离术后,最小直径大于650微米的黄斑孔在85%的病例中会闭合,并对视力有益
IF 3.9 3区 医学
Eye Pub Date : 2024-09-06 DOI: 10.1038/s41433-024-03302-y
Mehdi Bencheqroun, Aude Couturier, Ismael Chehaibou, Ramin Tadayoni, Elise Philippakis
{"title":"Macular holes with minimal diameter greater than 650 µm close in 85% of cases after vitrectomy and ILM peeling with visual benefit","authors":"Mehdi Bencheqroun, Aude Couturier, Ismael Chehaibou, Ramin Tadayoni, Elise Philippakis","doi":"10.1038/s41433-024-03302-y","DOIUrl":"https://doi.org/10.1038/s41433-024-03302-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To describe the postoperative outcomes of eyes with primary full-thickness macular holes (MH) greater than 650 μm.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>Retrospective, monocentric, consecutive case series.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>Patients with primary MH operated at Lariboisière Hospital, Paris, France.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Records of patients with MH with a minimum horizontal diameter greater than 650 μm that underwent primary surgery with internal limiting membrane (ILM) peeling (complete or with inverted ILM flap) between January 2010 and January 2022 were reviewed.</p><h3 data-test=\"abstract-sub-heading\">Main outcome measures</h3><p>Postoperative MH closure rate and visual acuity.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>74 eyes of 73 patients met the inclusion criteria. The mean minimum horizontal diameter was 777 ± 108 µm (650-1114). It ranged between 650 and 800 µm in 40 eyes (54%) and was <span>≧</span> 800 µm in 34 eyes (46%). The closure rate was 77% (57/74) after primary surgery and was significantly higher in MH between 650 and 800 µm, than in MH <span>≧</span> 800 µm (87.5% versus 64.7%, p = 0.02). In the 58/74 eyes in which conventional ILM peeling was performed, closure rate was 74.1% (43/58), significantly higher in MH ranging between 650 and 800 µm than in MH <span>≧</span> 800 µm (84.8% versus 60.0%, p = 0.03). In closed MH, 50/64 (78%) eyes achieved a VA gain ≥0.2 logMAR (3 lines), and 14 (21.9%) eyes a final BCVA ≥ 0.3 logMAR.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>MH surgery with conventional ILM peeling allowed closed MH <span>≧</span> 650 μm and &lt; 800 μm with a success rate close to 85% that decreased in larger MH. A significant visual improvement was achieved after MH closure, even in MH <span>≧</span> 800 μm.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142191122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomic and functional prognosis of vitreoretinal surgery in rhegmatogenous retinal detachment associated with intraocular inflammation. 对伴有眼内炎症的流变性视网膜脱离进行玻璃体视网膜手术的解剖和功能预后。
IF 2.8 3区 医学
Eye Pub Date : 2024-09-06 DOI: 10.1038/s41433-024-03300-0
Adam Mainguy, Michel Weber, Adélaïde Toutée, Christine Fardeau, Olivier Lebreton, Hélène Massé, Bahram Bodaghi, Sara Touhami
{"title":"Anatomic and functional prognosis of vitreoretinal surgery in rhegmatogenous retinal detachment associated with intraocular inflammation.","authors":"Adam Mainguy, Michel Weber, Adélaïde Toutée, Christine Fardeau, Olivier Lebreton, Hélène Massé, Bahram Bodaghi, Sara Touhami","doi":"10.1038/s41433-024-03300-0","DOIUrl":"https://doi.org/10.1038/s41433-024-03300-0","url":null,"abstract":"<p><strong>Background/objectives: </strong>The predictive factors of surgical results in uveitic retinal detachment (RD) are lacking. The objective was to study the surgical outcomes and determine the risk factors for surgical failure in rhegmatogenous RD associated with intraocular inflammation (RRDIOI).</p><p><strong>Methods: </strong>Retrospective series of consecutive eyes with RRDIOI undergoing vitreoretinal surgery between 2012 and 2019 in two French referral centres. Patients underwent 23- or 25 G pars plana vitrectomy (PPV), scleral buckling (SB), or a combination of both. The main objective was to describe the predictive factors of visual recovery and anatomical success after surgery.</p><p><strong>Results: </strong>Seventy-one eyes were included. Posterior and panuveitis accounted for 91.5% of eyes. Seventy-five percent of eyes had an infectious cause for their uveitis. The first surgery consisted in PPV alone, SB alone, or both in 87.3%, 4.2% and 8.5% of cases respectively. The reattachment rate was 74.6% after one surgery (100% in case of SB, either alone or in association with PPV). On multivariate analysis, the only predictive factor of visual improvement was a baseline BCVA ≥ 20/400, while the only predictive factor for surgical success at 12 months was the absence of RD recurrence within the first 6 weeks of surgery.</p><p><strong>Conclusions: </strong>RRDIOI has a relatively favourable anatomical prognosis. The addition of scleral buckling may be beneficial in selected cases.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Costs and cost-effectiveness of the Kerala pilot screening programme for diabetic retinopathy in the public health system. 喀拉拉邦公共卫生系统糖尿病视网膜病变试点筛查计划的成本和成本效益。
IF 2.8 3区 医学
Eye Pub Date : 2024-09-03 DOI: 10.1038/s41433-024-03304-w
Raphael Wittenberg, Robert Anderson, Stuart Redding, Bipin Gopal, Rajeev Sadanandan, Vasudeva Iyer Sahasranamam, Simon George, Lakshmi Premnazir, Gopalakrishnan Netuveli, Jyotsna Srinath, Radha Ramakrishnan, Dolores Conroy, Sobha Sivaprasad
{"title":"Costs and cost-effectiveness of the Kerala pilot screening programme for diabetic retinopathy in the public health system.","authors":"Raphael Wittenberg, Robert Anderson, Stuart Redding, Bipin Gopal, Rajeev Sadanandan, Vasudeva Iyer Sahasranamam, Simon George, Lakshmi Premnazir, Gopalakrishnan Netuveli, Jyotsna Srinath, Radha Ramakrishnan, Dolores Conroy, Sobha Sivaprasad","doi":"10.1038/s41433-024-03304-w","DOIUrl":"https://doi.org/10.1038/s41433-024-03304-w","url":null,"abstract":"<p><strong>Background/objectives: </strong>The Government of Kerala initiated a pilot screening programme for diabetic retinopathy in 16 Family Health Centres in Thiruvananthapuram district in 2019 in collaboration with the ORNATE India project. The evaluation of this pilot included a study of its costs and cost-effectiveness to inform decisions about extending the programme throughout Kerala.</p><p><strong>Subjects/methods: </strong>The participants comprise all 5307 people who were screened for diabetic retinopathy under the pilot programme for whom data could be collected.</p><p><strong>Results: </strong>The costs of the pilot programme are estimated at INR 11.3 million (including INR 1.9 million costs to individuals) and the benefits at 514 QALYs, slightly over one QALY per person treated. The cost per QALY was INR 22,000, which is well below India's Gross National Income per person.</p><p><strong>Conclusions: </strong>Kerala's 2019 pilot screening programme for diabetic retinopathy was highly cost-effective.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信